Background Non-small cell lung cancer (NSCLC) with TP53 mutations has a worse prognosis. It was generally more resistant to chemotherapy and radiation. Our aim was to investigate the correlation between the TP53 co-mutated gene and clinical features, and prognostic value in patients with NSCLC. Methods Seventy-three patients with a diagnosis of NSCLC at our hospital were recruited. They were divided into the TP53 mutation status (minor) (TP53 MU) and TP53 wild-type (major) (TP53 WT) groups according to their clinical characteristics after their mutation data and clinical information were collected. Serum markers were compared between groups using Mann-Whitney U test. Other clinical factors were compared between groups using χ2 test and Fisher exact test. The log-rank test was used to compare survival curves. Results Of the 73 patients with NSCLC, 37 (50.68%) were found to carry TP53 mutation. TP53 MU and TP53 WT groups (n = 36) showed a significant difference in the number of smokers, incidence of squamous cell carcinoma, EGFR mutation, and number of advanced patients (P < .05), while gender, age, lymph node metastasis, and KRAS mutation did not differ significantly between the 2 groups. The survival curves in the TP53/KRAS and the TP53/EGFR co-mutation groups suggest that patients with NSCLC may have a shorter progression-free survival (PFS) if they carry one of the 2 types of co-mutation. Conclusions TP53 gene mutations are more common in patients with NSCLC and squamous cell carcinoma. New predictive markers for NSCLC prognosis may be TP53/KRAS and TP53/EGFR co-mutations.

中文翻译：

---

TP53突变与非小细胞肺癌预后临床特征的相关性分析。

背景 TP53 突变的非小细胞肺癌 (NSCLC) 预后较差。它通常对化疗和放疗具有更强的抵抗力。我们的目的是研究 TP53 共突变基因与 NSCLC 患者临床特征和预后价值之间的相关性。方法 纳入73例在我院诊断为NSCLC的患者。收集突变数据和临床信息后，根据临床特征将其分为TP53突变状态（轻微）（TP53 MU）和TP53野生型（主要）（TP53 WT）组。使用曼-惠特尼 U 检验比较组间血清标志物。组间其他临床因素的比较采用χ2检验和Fisher精确检验。对数秩检验用于比较生存曲线。结果 73例NSCLC患者中，37例（50.68%）被发现携带TP53突变。TP53 MU 和 TP53 WT 组 (n = 36) 在吸烟人数、鳞状细胞癌发生率、EGFR 突变和晚期患者人数方面存在显着差异 (P < .05)，而性别、年龄、淋巴结转移情况，KRAS 突变在两组之间没有显着差异。TP53/KRAS 和 TP53/EGFR 共突变组的生存曲线表明，如果 NSCLC 患者携带两种类型共突变之一，则其无进展生存期 (PFS) 可能较短。结论 TP53基因突变在NSCLC和鳞癌患者中更为常见。NSCLC 预后的新预测标志物可能是 TP53/KRAS 和 TP53/EGFR 共突变。